News Novartis AG

Equities

NOVN

CH0012005267

Real-time Estimate Cboe Europe Other stock markets 03:35:49 2024-04-25 am EDT			5-day change	1st Jan Change
90.78 ^CHF	+1.86%		+7.15%	+6.70%

Apr. 24	BMO Capital Adjusts Price Target on Novartis to $116 From $114, Maintains Market Perform Rating	MT
Apr. 24	Novartis Says New Malaria Drug Formulation Safe and Effective for Babies	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BMO Capital Adjusts Price Target on Novartis to $116 From $114, Maintains Market Perform Rating	Apr. 24	MT
Novartis Says New Malaria Drug Formulation Safe and Effective for Babies	Apr. 24	MT
Dpa-AFX Overview: COMPANIES from 24.04.2024 - 15:15	Apr. 24	DP
NOVARTIS AG : UBS reaffirms its Buy rating	Apr. 24	ZD
NOVARTIS AG : Deutsche Bank gives a Buy rating	Apr. 24	ZD
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump	Apr. 24	RE
Novartis: positive data for malaria treatment	Apr. 24	CF
NOVARTIS AG : JP Morgan remains Neutral	Apr. 24	ZD
Novartis, Medicines for Malaria Say Treatment for Babies Shows Efficacy	Apr. 24	DJ
Novartis Partnership Says New Malaria Drug for Babies Effective, Safe in Phase 2/3 Trial	Apr. 24	MT
Novartis Faces Lawsuit for Illegal Promotion of Asthma Drug as Preterm Labor Treatment	Apr. 24	MT
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria	Apr. 24	GL
Novartis and Medicines for Malaria Venture Announce Positive Efficacy and Safety Data for A Novel Treatment for Babies	Apr. 24	CI
Novartis Receives FDA Approval for Gastroenteropancreatic Tumor Treatment in Pediatric Patients	Apr. 23	MT
Novartis, Danaher rise; Nucor, Cadence Design Systems fall, Tuesday, 4/23/2024	Apr. 23	AQ
US Equity Markets Close Higher Tuesday	Apr. 23	MT
Novartis Wins FDA Approval of Pancreatic Tumor Therapy in Children	Apr. 23	MT
Novartis Gets FDA Approval for Lutathera in Pediatric Treatment	Apr. 23	DJ
Novartis radioligand therapy Lutathera(R) FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors	Apr. 23	DJ
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors	Apr. 23	GL